Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,580,006
  • Shares Outstanding, K 70,129
  • Annual Sales, $ 0 K
  • Annual Income, $ -209,340 K
  • 60-Month Beta 3.16
  • Price/Sales 7.14
  • Price/Cash Flow N/A
  • Price/Book 28.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.68
  • Number of Estimates 3
  • High Estimate 0.73
  • Low Estimate 0.64
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +173.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.50 +28.74%
on 01/27/20
23.03 -2.17%
on 02/20/20
+3.25 (+16.86%)
since 01/21/20
3-Month
16.81 +34.03%
on 01/06/20
23.03 -2.17%
on 02/20/20
+4.04 (+21.85%)
since 11/21/19
52-Week
12.95 +73.98%
on 04/01/19
23.91 -5.77%
on 09/25/19
+7.59 (+50.80%)
since 02/21/19

Most Recent Stories

More News
Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today announced that effective February 18, 2020, the compensation committee of the Company's board of directors granted options to...

CHRS : 22.53 (+0.13%)
Shares of CHRS Up 12.1% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Coherus Bioscien (NASDAQ:CHRS) on January 15th, 2020 at $19.59. In approximately 1 month, Coherus Bioscien has returned 12.15% as of today's recent price of $21.97....

CHRS : 22.53 (+0.13%)
After Yesterday's Rally of 3.93% Shares Could Potentially Pullback

Coherus Bioscien (NASDAQ:CHRS) traded in a range yesterday that spanned from a low of $20.60 to a high of $21.80. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high...

CHRS : 22.53 (+0.13%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CHRS , ESPR , ABBV , NVTA , CYTK )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ABBV : 94.96 (+0.77%)
CHRS : 22.53 (+0.13%)
ESPR : 61.76 (-9.64%)
Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why

Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CHRS : 22.53 (+0.13%)
Coherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th

Coherus BioSciences, Inc. ("Coherus" or "the Company", Nasdaq: CHRS), today announced that its fourth quarter and full year 2019 financial results will be released after market close on Thursday, February...

CHRS : 22.53 (+0.13%)
Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?

Is (CHRS) Outperforming Other Medical Stocks This Year?

CHRS : 22.53 (+0.13%)
Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status

The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.

CHRS : 22.53 (+0.13%)
ARNA : 52.69 (-1.01%)
AVXL : 5.09 (-1.36%)
UTHR : 106.96 (-0.43%)
Chris Lehman Joins Avellino Labs As Chief Financial Officer

Avellino Labs, global biotechnology and precision medicine innovators, announced today that Chris Lehman has joined the company as Chief Financial Officer (CFO). Mr. Lehman brings to the role over twenty-five...

CHRS : 22.53 (+0.13%)
Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada

Innovent Biologics, Inc. ("Innovent" or the "Company") (HKEX: 01801), a biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic...

CHRS : 22.53 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade CHRS with:

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

2nd Resistance Point 23.09
1st Resistance Point 22.81
Last Price 22.53
1st Support Level 22.16
2nd Support Level 21.79

See More

52-Week High 23.91
Last Price 22.53
Fibonacci 61.8% 19.72
Fibonacci 50% 18.43
Fibonacci 38.2% 17.14
52-Week Low 12.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar